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Summary This study was aimed to quantitatively evaluate the effects of topiramate
(TPM) on seizure susceptibility and hippocampal peripheral-type benzodiazepine
receptors (PBRs) in the kainic acid (KA) model of temporal lobe epilepsy. Male rats
were randomized into saline control group, KA group, KA/TPM low dose group and KA/
TPM high dose group. Three weeks after single injection of KA (10 mg kg1, sc), the
effects of TPMwere tested at two doses (10 and 30 mg kg1, sc) once a day for 1week in
KA/TPM low dose group or KA/TPM high dose group, respectively. Rats in KA group
received comparable injections of saline. Four weeks after initial KA injection, a
subconvulsant dose KA (5 mg kg1, sc) was administered in rats in these three groups.
Rats in saline control group received equal volume of saline. All animals were decapi-
tated and hippocampus synaptosomes were purified 180 min after behavioral observa-
tion. PBRs specific binding sites were assessed by an in vitro binding technique utilizing
the highly selective ligand [3H]PK11195. Seizure threshold was elevated and specific
PBRs binding in hippocampuswas decreased byTPM indose-dependentmanner. Specific
PBRs binding in hippocampus was significantly related to seizure latency and seizure
intensity. These results suggest that TPMcan reduce the susceptibility to seizures in KA-
kindled rats and its anticonvulsant effect seems resulting from, at least in part, the
reduced PBRs binding after treatment. These results also support the hypothesis that
PBRs represent a novel target for antiepileptic drug development.
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The peripheral-type benzodiazepine receptors
(PBRs) are distinct from the central-type benzodia-
zepine receptors structurally, functionally and phar-
macologically. PBRs are a multimeric complex found
mainly on the outer mitochondrial membrane of
astrocytes. PBRs may also be colocalized with acti-
vated microglia in injured brain tissue. PBRs are
composed with three subunits, an 18 kDa isoquino-
line carboxamide-binding protein, a 34 kDa voltage-
dependent anion channel and a 30 kDa adenine
nucleotide carrier. PBRs have been identified with
various physiological functions, such as steroidogen-
esis, respiration, cell growth and differentiation.
Increased PBRs expression was associated with both
microglial activation and astrogliosis enhancement.
Increased binding sites for PBRs ligands have been
described in a wide range of neurological disorders
including seizure in both human and animal.1
In spite of the rapid development of new antiepi-
leptic drugs over the past 20 years, approximately
30% of patients are still refractory to all types of
treatments. Thus, the searches for new mechanisms
of action that can regulate cellular excitability are
vitally needed. Topiramate (TPM) is a widely used
antiepileptic agent. In vitro studies suggested that
TPM affects neuronal activity and produces its anti-
epileptic effects by several mechanisms, but which
precise mechanism of function is poorly understood.
The aim of this study was tomeasure PBRs expression
in hippocampus from KA-induced epileptic rats and
test theeffects of TPMon seizure threshold andPBRs.Materials and methods
Materials
TPM was purchased from Janssen Pharmaceutical
Ltd. [3H]PK11195 (specific activity, 83.5 Ci/mmol;
radiochemical purity, 97%) was purchased from Per-
kinElmer Life Sciences (Boston, MA). Kainic acid
(KA), sucrose, bovine serum albumin, POPOP and
unlabelled PK11195 were purchased from Sigma
Chemical Co. (St. Louis, MO). PPO and Coomassie
brilliant blue G-250 were purchased from Fluka Ltd.
(Buchs, Switzerland). Triton X-100 was purchased
from Amersham Pharmacia Biotech, Inc. (Uppsala,
Sweden). Other chemicals, of reagent grade or
better, were from standard commercial suppliers.
Preparation of the reagents
Sucrose buffer (0.25 M sucrose, 1 mM EDTA, 10 mM
HEPES—NaOH, pH 7.4) and 0.8 M sucrose solution(0.8 M sucrose, 1 mM EDTA, 10 mM Tris—HCl, pH 7.4)
were prepared with distilled water. PK11195 was
dissolved in DMSO, and then diluted with phosphate-
buffered saline (PBS) to produce test solution. PPO
and POPOP dissolved in toluene and Triton X-100
were used as scintillates. TPM and KAwere dissolved
in saline at suitable concentrations for injection,
respectively. All experiments were done under
approved animal protocols.
Preparation of the rat model
Male Sprague—Dawley (SD) rats (180—220 g, n = 24)
were provided by Beijing Experimental Animal Cen-
ter (Beijing, China). The ratswere housed solitarily in
plastic cage under standard conditions (light/dark
cycle, 7:00 a.m.—7:00 p.m. lights on), with food and
water available ad libitum. Temperature (22 8C) and
humidity (60%) were kept constant. All animals
were acclimated to their home cages for at least 5
days before testing. Experiments were conducted
between 9:00 a.m. and 3:00 p.m. in an experimental
room. Animals were randomly divided into saline
control group, KA group, KA/TPM low dose group
and KA/TPM high dose group. All KA-treated rats
(n = 18) received KA (10 mg kg1, 1 ml kg1, sc).
The rats were immediately placed in individual Plex-
iglas containers (14 cm  25 cm  36 cm high) for
behavioral observation. Three weeks after KA injec-
tion (10 mg kg1), the effects of TPM were tested at
two doses (10 mg or 30 mg kg1, 1 ml kg1, sc) once a
day for 1week in KA/TPM lowdose group andKA/TPM
high dose group, respectively. Rats in KA group
received comparable injections of saline. Fourweeks
after initial KA injection, KA (5 mg kg1, 1 ml kg1,
sc)was injected in all KA-induced seizure rats. Rats in
saline control group received equal volume of saline.
Behavioral observation
Occurrence of spontaneous recurrent seizures was
video-recorded for 10 h following the initial KA
treatment and for 180 min following the second
KA treatment in all rats. Seizure threshold was
based on the severity of the seizures and the latency
from KA injection to seizures. The seizures were
divided into five stages according to their severity as
described previously.2 Latency was measured as the
time to onset of the first physical sign of seizures,
forelimb clonus. Videotapes were reviewed and
detected seizures were scored.
Preparation of synaptosomal fractions
Rats were anesthetized with pentobarbital sodium
solution (50 mg/kg) and then decapitated after
360 CF. Chen et al.
Figure 1 Seizure latency after kainic acid injection
in subthreshold dosage. The values are presented
as means  S.D. (n = 6). ~p < 0.01, ~~p < 0.001 or
~p < 0.001, compared with KA group or KA/TPM 10 mg
group, respectively.180 min of behavioral observation. Synaptosomes
from hippocampus were purified with a AvantiTM
J-30 centrifuge (Bechman) as described by Hajo´s3.
The purified synaptosome pellets were frozen on
liquid nitrogen and stored at 80 8C until radioli-
gand-binding assay.
[3H]PK11195 binding and scatchard
analysis
[3H]PK11195 filtration binding assays were per-
formed with liquid scintillation spectrometry (Bech-
man LS9800) as described earlier.4 Total binding of
[3H]PK11195 was determined for concentrations
ranging at six different final concentrations from
0.6 to 8.0 nM in duplicate. Binding parameters,
equilibrium dissociation constant (KD) and maximal
binding site density (Bmax), were estimated using
the LIGAND in KELL Version 6 program for Windows
(Biosoft, Cambridge, UK). Protein concentration
was determined by Bradford protein assay using
bovine serum albumin as standard.
Statistical methods
Data analysis was performed using SPSS Version 10.0
for Windows (SPSS Inc., Chicago, IL). Data obtained
from seizure latency and seizure severity scores
were expressed as means  S.D. and analyzed by
ANOVA with Scheffe post hoc test. The relationships
between indexes were calculated using the Pearson
correlation method. The level of significance was
defined as p < 0.05.Figure 2 Changes of seizure intensity after kainic acid
injection in subthreshold dosage. Data points are
mean  S.D. ~p < 0.01, ~~p < 0.001 or ~p < 0.05, com-
pared with KA group or KA/TPM 10 mg group, respectively.Results
All KA-treated animals were observed to have
spontaneous recurrent motor seizures following
the initial and secondary KA injections once
epilepsy has developed, while none were observed
in the saline-treated controls. Hence, saline-trea-
ted control group was ruled out from following
statistical analysis for seizure behavior. When
compared with KA group, the seizure latency pro-
longed by 97.3% or 231.2% in KA/TPM low dose
group or KA/TPM high dose group, respectively
(Fig. 1).
Seizure stage 5 was first seen about 90 min post-
KA (5 mg kg1) injection in KA group. No seizures
were recorded in 30 min or 60 min after secondary
KA injection in KA/TPM low dose group or KA/TPM
high dose group, respectively. In other phase of
seizure activity, seizure scores were lower in KA/
TPM low dose group or KA/TPM high dose group than
those in KA group, respectively (Fig. 2).No significant difference was found in the KD, one
saturation binding parameter for the binding of the
PBRs ligand [3H]PK11195 to synaptic membrane pre-
parations, values between each of the four groups
(F = 5.012, p > 0.05). On the contrary, the Bmax
values were significantly different among all groups
(F = 26.058, p < 0.001). A significant 78.6% increase
(p < 0.001) in Bmax was observed in KA group when
compared with control. Bmax decreased by 22.8% or
41.6% in KA/TPM low dose group or KA/TPM high
dose group when compared with KA group, respec-
tively (Table 1).
Bmax values of PBRs in hippocampal synaptosomes
were related to seizure latency and the mean sei-
zure intensity in 180 min after behavioral observa-
tion in KA, KA/TPM low dose and KA/TPM high dose
groups (Table 2). No significant correlation was
detected concerning KD and seizure threshold in
any one of the three groups ( p > 0.05).
By pooling seizure rats of all groups, Bmax values
of PBRs in hippocampal synaptosomes were related
to seizure latency (R = 0.852, p < 0.001, n = 18)
Topiramate effects on seizure susceptibility in kainate-kindled rats 361
Table 1 [3H]PK11195 binding parameters on synaptosomal membranes in rat hippocampus
Groups n Bmax (S.D.) (fmol/mg prot.) KD (S.D.) (nM)
Saline control 6 321.7  98.5 0.481  0.09
KA 6 574.5  94.4c 0.484  0.08
KA/TPM low dose 6 443.6  81.8bd 0.479  0.08
KA/TPM high dose 6 335.4  74.5 fg 0.474  0.07
bp < 0.01, cp < 0.001 vs. saline control group; dp < 0.05, fp < 0.001 vs. KA group; gp < 0.05 vs. KA/TPM low dose group.
Table 2 R- and p-values for correlations with the variables of seizure latency, mean seizure intensity and specific
[3H]PK11195 binding
Bmax in groups Seizure latency Mean seizure intensity
R-values p-values R-values p-values
KA 0.948 0.004 0.911 0.012
KA/TPM low dose 0.932 0.007 0.875 0.022
KA/TPM high dose 0.841 0.036 0.823 0.044
Number of rats is six in each of the groups.andmaximal seizure intensity (R = 0.838, p < 0.001,
n = 18) (Fig. 3). No significant correlation was found
between KD values and seizure threshold para-
meters ( p > 0.05).Discussion
Temporal lobe epilepsy (TLE) is one of the most
common forms of intractable epilepsy. Frequently
associated with these recurrent complex partial
seizures is the presence of hippocampal sclerosis
(HS) with specific neuronal loss in hippocampus.
Injection of KA induces generalized convulsive sta-
tus epilepticus (SE) in rodents, which represents the
initial precipitating injury. After a latent period,
adult rats exhibit spontaneous recurrent seizures
during the remainder of their life.5 Because of
the relevance of this model to human pathology,Figure 3 Relationships between seizure latency, maximal se
induced epileptic rats were produced by pretreatment of kain
acute KA seizures (5 mg kg1, sc). PBRs binding to themembran
radioactive antagonist [3H]PK11195. A liner relationship betwe
of PBRs were detected by Pearson correlation test ( p < 0.00the KA model can be used to test the effects of
drugs.6 An association between alterations of PBRs
and epilepsy has been proposed. There is concei-
vably a role for PBRs activation in the pathogenesis
of the epileptic process per se. KA-induced epileptic
rats showed increased brain densities of PBRs sites.7
It was suggested that these increases in PBRs sites
were either the consequence of the epileptogenic
process per se or resulted from the gliosis accom-
panying neuronal cell loss in hippocampus of epi-
leptic animals.8,9 Results of the present study
indicated that higher susceptibility to KA-induced
seizures were related to increased binding sites of
[3H]PK11195 in hippocampus in rats. These findings
confirmed and extended those of previous studies
which observed increased PBRs sites in the blood
mononuclear cells10 and the brain11 in patients with
epilepsy. Hippocampal sclerosis and hyperexcitabil-
ity are neuropathological features of human TLEizure intensity and specific [3H]PK11195 binding. Kainate-
ic acid (KA, 10 mg kg1, sc) 4 weeks prior to induction of
e of synaptosomes from hippocampus were assayed by the
en the parameters of seizure threshold and the Bmax values
1, n = 18).
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in rats.5,6,9 PBRs was mainly found on the membrane
of astrocytes.1 Immunohistochemical studies
revealed increased PBRs immunolabeling in CA1
subfield of TLE patients with hippocampal sclerosis.
The increased immunolabeling was particularly
localized on astrocytic elements suggesting that
the increased PBRs signal was the consequence of
astrogliosis which accompanied neuronal cell loss in
TLE.11 Similar findings of increased PBRs sites coin-
cident with astrocytic proliferation in the presence
of neuronal loss were previously reported in Alzhei-
mer’s disease and Wernicke’s encephalopathy.1 On
the other hand, PBRs were also colocalized with
activated microglia in injured brain tissue. Other
disorders, such as multiple sclerosis12 and stroke-
induced brain injury,13 have been described with
increased PBRs sites coinciding with activating
microglia rather than astrocytes. KA treatment
induces Ammon’s horn sclerosis, which is character-
ized by neurons degeneration and reactive gliosis.
The glial reaction consists of a proliferation and
hypertrophy of astrocytes and microglia macro-
phages. Novel findings in the present study of a
correlation between the increased PBRs sites with
seizure latency and seizure severity in all seizure
rats suggest that PBRs binding in hippocampus was
related to the increased long-term susceptibility to
seizures. It has been reported that pre-treatment
with the PK11195, a specific PBRs antagonist, can
attenuate the occurrence of seizures.7 Nefiracetam
may inhibit spontaneous seizures in EL mice through
interacting with PBRs.14 Together with these results
indicate that PBRs could represent a novel target for
antiepileptic drug development. Nonetheless, the
potential action of PBRs on seizures has not been
used in animal models to screen antiepileptic drugs
that block these receptors.
TPM [2,3:4,5-bis-O-(1-methylethylidene)-36-D-
fructopyranose sulfamate] is a structurally novel
antiepileptic drug that is approved for use in the
treatment of refractory partial-onset seizures in
adults, partial-onset seizures in children, and gen-
eralized tonic—clonic seizures of nonfocal origin.15
Several cellular mechanisms have been proposed
for the therapeutic effects of TPM, including (1)
activity-dependent attenuation of voltage-depen-
dent sodium and calcium currents; (2) potentiation
of GABAA-receptor-mediated currents; (3) inhibi-
tion of AMPA/kainate receptors; and (4) TPM has a
weak inhibitory effect on some carbonic anhydrase
isoenzymes.16 The relative importance of any of
these mechanisms in the clinical activity of TPM is
not well defined. The experiments reported here
showed that TPM has powerful ameliorating
effects, accompanied by PBRs decreases, on KA-induced seizures in a dose-dependent manner. Sur-
prisingly, PBRs expression in hippocampus returned
to normal level after TPM treatment in 30 mg kg1
in rats. Findings in the present study suggest that
the neuronal activity and antiepileptic effects of
TPM may be functioned through PBRs mechanisms.
At the same time, our results, as shown in Table 1,
also indicated that TPM did not change the affinity
of PBRs, but increased the number of binding sites in
hippocampus synaptosomal membranes. With the
knowledge of the pharmacological properties of
TPM, several of its mechanisms of action could be
expected to have neuroprotective properties. TPM
exhibits neuroprotective properties in severalmod-
els of injury such as global ischemia,17 focal ische-
mia,18 SE19,20 or other neurological and systemic
diseases.21 Most patients with TLE, the most com-
mon type of epilepsy, showed pronounced loss of
neurons in limbic brain regions, including the hip-
pocampus. The massive neurodegeneration in the
hippocampus is known as HS, and is considered one
of the hallmarks of this type of difficult-to-treat
epilepsy. Previous studies revealed that single
(40 mg kg1) or repeated doses of TPM (30 mg kg1)
1) given after experimental seizures can prevent
the increase in susceptibility to KA seizure-induced
hippocampal neuronal injury in rats and this pro-
tection occurs independent of its anticonvulsant
action.22,23 Neuroprotective properties of TPM
could explain the present results.
In conclusion, higher profile of the PBRs binding
sites in hippocampus synaptosomal membranes is
associated with the increase in susceptibility to KA-
induced seizures in rats. Inhibition of PBRs may
represent one mechanism through which TPM
increases seizure threshold.References
1. Lang S. The role of peripheral benzodiazepine receptors
(PBRs) in CNS pathophysiology. Curr Med Chem 2002;9:
1411—5.
2. Racine RJ. Modification of seizure activity by electrical sti-
mulation. II. Motors seizure. Electroencephlogr Clin Neuro-
physiol 1972;32:281—94.
3. Hajo´s F. An improved method for the preparation of synap-
tosomal fraction in high purity. Brain Res 1975;93:485—9.
4. Rao VLR, Butterworth RF. Characterization of binding sites for
the omega3 receptor ligands [3H]PK11195 and [3H]RO5-4864
in human brain. Eur J Pharmacol 1997;340:89—99.
5. Hellier JL, Patrylo PR, Buckmaster PS, Dudek FE. Recurrent
spontaneous motor seizures after repeated low-dose sys-
temic treatment with kainate: assessment of a rat model
of temporal lobe epilepsy. Epilepsy Res 1998;31:73—84.
6. Sperk G. Kainic acid seizures in the rat. Prog Neurobiol
1994;42:1—32.
7. Veenman L, Leschiner S, Spanier I, Weisinger G, Weizman A,
Gavish M. PK11195 attenuates kainic acid-induced seizures
Topiramate effects on seizure susceptibility in kainate-kindled rats 363and alterations in peripheral-type benzodiazepine receptor
(PBR) protein components in the rat brain. J Neurochem
2002;80:917—27.
8. Sloviter RS. Decreased hippocampal inhibition and a selective
loss of interneurons in experimental epilepsy. Science
1987;235:73—6.
9. Katzir H, Mendoza D, Mathern GW. Effect of theophylline and
trimethobenzamide when given during kainate-induced sta-
tus epilepticus: an improved histopathologic rat model of
human hippocampal sclerosis. Epilepsia 2000;41:1390—9.
10. Caldiroli E, Marino F, Cosentino M, De-Ponti F, Fietta AM,
Mazzone A, et al. Peripheral benzodiazepine receptor
expression on leukocytes and neutrophil function during
anticonvulsant monotherapy. Pharmacology 1998;57:
215—21.
11. Sauvageau A, Desjardins P, Lozeva V, Rose C, Hazell AS,
Bouthillier A, et al. Increased expression of ‘‘peripheral-
type’’ benzodiazepine receptors in human temporal lobe
epilepsy: implications for PET imaging of hippocampal sclero-
sis. Metab Brain Dis 2002;17:3—11.
12. Banati RB, Newcombe J, Gunn RN, Cagnin A, Turkheimer F,
Heppner F, et al. The peripheral-type benzodiazepine binding
site in the brain in multiple sclerosis: quantitative in vivo
imaging of microglia as a measure of disease activity. Brain
2000;123:2321—37.
13. Stephenson DT, Schober DA, Smaltig EB, Mincy E, Gehlert DR,
Clemens JA. Peripheral benzodiazepine receptors are colo-
calized with activated microglia following transient global
forebrain ischemia in the rat. J Neurosci 1995;15:5263—74.
14. Nakamoto Y, Shiotani T, Watabe S, Nabeshima T, Yoshii M.
Nootropic nefiracetam inhibits proconvulsant action ofperipheral-type benzodiazepines in epileptic mutant EL
mice. Ann N Y Acad Sci 2004;1025:135—9.
15. LaRoche SM, Helmers SL. The new antiepileptic drugs: scien-
tific review. JAMA 2004;291:605—14.
16. Czapinski P, Blaszczyk B, Czuczwar SJ. Mechanisms of action
of antiepileptic drugs. Curr Top Med Chem 2005;5:3—14.
17. Edmonds Jr HL, Jiang YD, Zhang PY, Shank R. Topiramate as a
neuroprotectant in a rat model of global ischemia-induced
neurodegeneration. Life Sci 2001;69:2265—77.
18. Yang Y, Li Q, Shuaib A. Enhanced neuroprotection and
reduced hemorrhagic incidence in focal cerebral ischemia
of rat by low dose combination therapy of urokinase and
topiramate. Neuropharmacology 2000;39:881—8.
19. Kudin AP, Debska-Vielhaber G, Vielhaber S, Elger CE, Kunz
WS. The mechanism of neuroprotection by topiramate in an
animal model of epilepsy. Epilepsia 2004;45:1478—87.
20. Rigoulot MA, Koning E, Ferrandon A, Nehlig A. Neuroprotec-
tive properties of topiramate in the lithium-pilocarpine
model of epilepsy. J Pharmacol Exp Ther 2004;308:787—95.
21. Trojnar MK, Malek R, Chroscinska M, Nowak S, Blaszczyk B,
Czuczwar SJ. Neuroprotective effects of antiepileptic drugs.
Pol J Pharmacol 2002;54:557—66.
22. Grabenstatter HL, Ferraro DJ, Williams PA, Chapman PL,
Dudek FE. Use of chronic epilepsy models in antiepileptic
drug discovery: the effect of topiramate on spontaneous
motor seizures in rats with kainate-induced epilepsy. Epilep-
sia 2005;46:8—14.
23. Koh S, Tibayan FD, Simpson JN, Jensen FE. NBQX or topir-
amate treatment after perinatal hypoxia-induced seizures
prevents later increases in seizure-induced neuronal injury.
Epilepsia 2004;45:569—75.
